3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
2
Skin Neoplasms
1
Skin Diseases
1
Neoplasms
1
Neoplasm Metastasis
1
Interventions
trastuzumab deruxtecan
4
eribulin
3
Capecitabine
3
Trastuzumab
2
Paclitaxel
2
Gemcitabine
2
Carboplatin
2
130-nm albumin-bound paclitaxel
2
telisotuzumab vedotin
1
taxane
1
pertuzumab
1
pembrolizumab
1
osimertinib
1
olaparib
1
margetuximab
1
exemestane
1
entrectinib
1
encorafenib
1
dacomitinib
1
capmatinib
1
binimetinib
1
adagrasib
1
abemaciclib
1
Vinorelbine
1
Vemurafenib
1
Pemetrexed
1
Imlunestrant
1
Gefitinib
1
Fulvestrant
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Neoplasm Metastasis
×
Vemurafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA